Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Frying Tumors Can Boost Lung Cancer Survival

And a similar needle-based freezing technology can help fight kidney cancer, studies find

By Amanda Gardner
HealthDay Reporter


Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Basal Cell Carcinoma
Bashful Bladder Syndrome
Bladder Cancer
More...

Related Healthscout Videos
 border=
Complementary Cancer Care
A Welcome Message from Survivor PJ Hamel
Smother Says "Cut!"
Maryann and Paula
More...

Related Animations
 border=
Breast Self-Exam Video
Colon Cancer
More...

Related Drug Information
 border=
Epogen
Iressa
Procrit
Topamax
More...

Related News Articles
 border=
Ethnicity May Drive Response to Obesity, Insulin Resistance
Smoking, Drinking Should Matter in Movie Ratings, Parent Survey Finds
Wine May Be Protective Against Esophageal Cancer
New Test May Mean Faster Breast Cancer Treatment
More...

MONDAY, March 17 (HealthDay News) -- Needle-delivered frying or freezing technologies can be useful weapons against both lung and kidney cancers, new research shows.

In one study conducted in France, patients with advanced lung cancer who were not candidates for surgery underwent a procedure known as radiofrequency ablation (RFA), which basically heats the tumors and kills them.

Text Continues Below



Seventy percent of the patients with lung metastases or primary non-small cell lung cancer were still alive after two years -- similar to results seen after surgery.

Furthermore, 85 percent of patients with non-small cell primary lung cancer treated with RFA had no viable tumors visible on imaging one year later, while 77 percent had no viable tumors after two years.

"It means that you can actually do a very good job of local control of lung tumors in patients who aren't fit for surgery," said Dr. Damian Dupuy, a professor of diagnostic imaging at Warren Alpert Medical School at Brown University and director of tumor ablation at Rhode Island Hospital in Providence.

"The medical establishment, being very conservative, has always said if you aren't fit for surgery you just basically get chemo and radiation and most of the time [they] don't work well and you die of your tumor. But even the most unfit for surgery can have this procedure safely," Dupuy said.

The Brown researcher was not involved in the French study, but his group completed a lung cancer trial last year with similarly good results.

The new study, led by Dr. Thierry de Baere of Institute Gustave Roussy, in Villejuif, France, was to be presented Monday at the annual meeting of the Society for Interventional Radiology in Washington, D.C.

Lung cancer is the number one cancer killer in the United States and a full 25 percent of patients who have operable disease can't undergo surgery because of co-existing conditions, Dupuy noted.

Page:  1 | 2 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 3/17/2008

Related Links
 border=
From Healthscout's partner site on incontinence, IncontinenceNetwork.com
Learn about urinary incontinence types, treatments, and more.
Get information about stress incontinence.
What is different about urge incontinence?





SOURCES: Christos S. Georgiades M.D. Ph.D., assistant professor, radiology and surgery, Johns Hopkins Hospital, Baltimore; Damian Dupuy, M.D., professor, diagnostic imaging, Warren Alpert Medical School at Brown University, and director, tumor ablation, Rhode Island Hospital, Providence; March 17, 2008, presentations, annual meeting, Society of Interventional Radiology, Washington, D.C.


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map